Evidence map›Paper›PMID 12022223›Full record

ArticleRNA (New York, N.Y.)2002

Mutation Master: profiles of substitutions in hepatitis C virus RNA of the core, alternate reading frame, and NS2 coding regions.

José L Walewski, Julio A Gutierrez, Westyn Branch-Elliman, Decherd D Stump, Toby R Keller, Alfredo Rodriguez, Gary Benson, Andrea D Branch

Open access · bronzeAbstract read
In one paragraph

Article in RNA (New York, N.Y.), 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 49 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Cell-mediated immune responses directed against hepatitis C virus (HCV) alternate reading frame protein (ARFP) are undetectable during acute infection.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2010
    Article
  8. Article
  9. Mutations in the hepatitis C virus core gene are associated with advanced liver disease and hepatocellular carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2009
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

José L WalewskiDepartment of Medicine, Division of Liver and Diseases, Mount Sinai School of Medicine, New York, New York 10029, USA.
Julio A Gutierrez
Westyn Branch-Elliman
Decherd D Stump
Toby R Keller
Alfredo Rodriguez
Gary Benson
Andrea D Branch
Icahn School of Medicine at Mount Sinai · US

Funding

RIBOZYMES AND RNA GENE THERAPIES FOR LIVER DISEASESR01DK052071 · NIDDK · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI BRANCH, ANDREA D. · 1997 to 2003
$475k
NIDDK NIH HHS R01 DK52071
6 · The paper itself

Abstract

The RNA genome of the hepatitis C virus (HCV) undergoes rapid evolutionary change. Efforts to control this virus would benefit from the advent of facile methods to identify characteristic features of HCV RNA and proteins, and to condense the vast amount of mutational data into a readily interpretable form. Many HCV sequences are available in GenBank. To facilitate analysis, consensus sequences were constructed to eliminate the overrepresentation of certain genotypes, such as genotype 1, and a novel package of sequence analysis tools was developed. Mutation Master generates profiles of point mutations in a population of sequences and produces a set of visual displays and tables indicating the number, frequency, and character of substitutions. It can be used to analyze hundreds of sequences at a time. When applied to 255 HCV core protein sequences, Mutation Master identified variable domains and a series of mutations meriting further investigation. It flagged position 4, for example, where 90% or more of all sequences in genotypes 1, 2, 4, and 5, have N4, whereas those in genotypes 3, 6, 7, 8, 9, and 10 have L4. This pattern is noteworthy: L (hydrophobic) to N (polar) substitutions are generally rare, and genotypes 1, 2, 4, and 5 do not form a recognized super family of sequences. Thus, the L4N substitution probably arose independently several times. Moreover, not one member of genotypes 1, 2, 4, or 5 has L4 and not one member of genotypes 3, 6, 7, 8, 9, or 10 has N4. This nonoverlapping pattern suggests that coordinated changes at position 4 and a second site are required to yield a viable virus. The package generated a table of genotype-specific substitutions whose future analysis may help to identify interacting amino acids. Three substitutions were present in 100% of genotype 2 members and absent from all others: A68D, R74K, and R114H. Finally, this study revealed thatARFP, a novel protein encoded in an overlapping reading frame, is as conserved as conventional HCV proteins, a result supporting a role for ARFP in the viral life cycle. Whereas most conventional programs for phylogenetic analysis of sequences provide information about overall relatedness of genes or genomes, this program highlights and profiles point mutations. This is important because determinants of pathogenicity and drug susceptibility are likely to result from changes at only one or two key nucleotides or amino acid sites, and would not be detected by the type of pairwise comparisons that have usually been performed on HCV to date. This study is the first application of Mutation Master, which is now available upon request (http://tandem.biomath.mssm.edu/mutationmaster.html).

Indexed as

MutationSoftwareAmino Acid MotifsAmino Acid SequenceComputational BiologyConsensus SequenceGenome, ViralGenotypeHepacivirusHumansMolecular Sequence DataPoint MutationProtein Structure, TertiaryReading FramesRNA, ViralSequence AlignmentNS2 protein, Hepatitis C virusRNA, ViralViral Core ProteinsViral Nonstructural Proteins

Identifiers

PMID12022223
PMCPMC1370277
OpenAlexW2149294770

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.